《加拿大健康》提醒患者,四氢噻唑二酮类或格列酮类的口服降糖药能引起体液潴留,加重充血性心衰。用药后若出现水肿、气短、虚弱、疲乏或体重增加应立即告之医师,以评价其治疗方案,若症状由充血性心衰所致,应停药。这与罗格列酮(rosiglitazone)和吡格列酮(pioglitazone)于2001年在加拿大上市时提供的安全性信息是一致的。 “Canadian Health” reminds patients that oral hypoglycemic agents such as tetrahydrothiazolones or glitazones cause fluid retention and worsen congestive heart failure. After treatment if edema, shortness of breath, weakness, fatigue or weight gain should be immediately informed of the physician to evaluate the treatment options, if the symptoms caused by congestive heart failure, should be discontinued. This is consistent with the safety information provided by rosiglitazone and pioglitazone when they were marketed in Canada in 2001.